Earnings ·
Kalaris Therapeutics reports Q3 net loss of $11.0M; extends cash runway into 2028
KLRSKalaris Therapeutics, Inc.
Kalaris Therapeutics reported a net loss of $11.0 million for the third quarter ended September 30, 2026, compared to an $11.9 million loss in the prior-year period. The company held $82.9 million in cash and marketable securities as of September 30, sufficient to fund operations into 2028. Management announced that preliminary data from its Phase 1b/2 study of TH103 for neovascular age-related macular degeneration is now expected in the second half of 2027 due to a manufacturing delay. Kalaris successfully completed technology transfer to a commercial-scale manufacturer, with test batches meeting target specifications. The company operates as a clinical-stage biopharmaceutical firm developing treatments for retinal diseases.